# EDGAR Filing Document

**Accession Number:** 0002126478
**File Stem:** 0000310158-26-000107
**Filing Date:** 2026-5
**Character Count:** 6464
**Document Hash:** 9bc229ae98e8ead40376feee526139c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000310158-26-000107.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0000310158-26-000107

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260501

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Maraldo David R.
- **CENTRAL INDEX KEY:** 0002126478

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-06571
- **FILM NUMBER:** 26939644

**MAIL ADDRESS:**
- **STREET 1:** 126 E. LINCOLN AVE.
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merck & Co., Inc.
- **CENTRAL INDEX KEY:** 0000310158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221918501
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065
- **BUSINESS PHONE:** 908-740-4000

**MAIL ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merck & Co. Inc.
- **DATE OF NAME CHANGE:** 20091103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SCHERING PLOUGH CORP
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Maraldo David R.<br><sub>(Last) (First) (Middle)</sub><br>126 EAST LINCOLN AVENUE<br><sub>(Street)</sub><br>RAHWAY, NJ 07065<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Merck & Co., Inc. [ MRK ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-05-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP & Pres. MMD_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 17819.434 | D |  |
| Common Stock - 401(k) Plan | 8359.14 | I | By 401 (k) |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | 2024-05-02<sup>(1)</sup> | 2026-05-02 | Common Stock | 552 | <sup>(2)</sup> | D |  |
| Restricted Stock Unit | 2025-04-30<sup>(3)</sup> | 2027-04-30 | Common Stock | 581 | <sup>(2)</sup> | D |  |
| Restricted Stock Unit | 2026-04-29<sup>(4)</sup> | 2028-04-29 | Common Stock | 2361 | <sup>(2)</sup> | D |  |
| Stock Option (Right to Buy) | 2022-05-04<sup>(5)</sup> | 2031-05-03 | Common Stock | 9465 | $73.73 | D |  |
| Stock Option (Right to Buy) | 2023-05-03<sup>(6)</sup> | 2032-05-02 | Common Stock | 9709 | $87.10 | D |  |
| Stock Option (Right to Buy) | 2024-05-02<sup>(7)</sup> | 2033-05-01 | Common Stock | 8990 | $117.89 | D |  |
| Stock Option (Right to Buy) | 2025-04-30<sup>(8)</sup> | 2034-04-29 | Common Stock | 8789 | $129.22 | D |  |
| Stock Option (Right to Buy) | 2026-04-29<sup>(9)</sup> | 2035-04-28 | Common Stock | 8060 | $84.71 | D |  |

---

### Footnotes:

(1) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025,and 5/2/2026.

(2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

(3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026, and, 4/30/2027.

(4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027, and, 4/29/2028.

(5) The options became exercisable in equal installments in on 5/4/2022, 5/4/2023, and 5/4/2024.

(6) The options became exercisable in equal installments in on 5/5/2024, 5/5/2025, and 5/5/2026.

(7) The options vest and become exercisable in equal installments on 5/2/2024, 5/2/2025, and 5/2/2026.

(8) The options vest and become exercisable in equal installments on 4/30/2025, 4/30/2026, and 4/30/2027.

(9) The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.

**Signature:** /s/ Kelly E. W. Grez as Attorney-in-Fact for David Maraldo  
**Date:** 2026-05-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**